‘Completely new’ cancer treatment strategy will start clinical trials in 2015
By Sharon Kingman
LONDON – The discovery of an enzyme that is vital to the survival of cancer cells, but which normal cells do not seem to need at all, is pointing to entirely new ways of treating cancer. Screening studies already have identified small-molecule inhibitors of the enzyme, and the Swedish team of researchers who made the discovery hopes to begin clinical trials with those compounds next year. So far, studies suggest that inhibiting the enzyme causes all types of cancer cells to die. It seems unlikely that the inhibitors will have side effects on a scale seen with most chemotherapy drugs.